FRED™ X™ Device for Brain Aneurysm

Not currently recruiting at 26 trial locations

Overseen By Amy Bowles

Age: 18+

Sex: Any

Trial Phase: Academic

Sponsor: Microvention-Terumo, Inc.

Must not be taking: Anticoagulants, Antiplatelets, Thrombolytics, others

Disqualifiers: Intracranial hemorrhage, Cardiac embolism, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Approved in 2 Jurisdictions This treatment is already approved in other countries

Compensation: Varies

Number of Visits: 1

Duration: 4 weeks

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial compares the new FRED™ X™ device, designed for treating brain aneurysms, to the existing FRED™ device. Brain aneurysms are bulges in blood vessels in the brain that can cause serious problems if they burst. The trial aims to determine if the new device is as safe and effective as the older one. Suitable candidates for this trial have a wide-necked aneurysm in a specific part of the brain artery. Participants must commit to follow-up visits for up to five years.

As an unphased trial, this study provides a unique opportunity to contribute to medical advancements in treating brain aneurysms.

Do I have to stop taking my current medications for the trial?

The trial protocol does not specify whether you need to stop taking your current medications. However, if you have a bleeding disorder or cannot tolerate anticoagulants (blood thinners) or antiplatelet agents, you may be excluded from the study.

What prior data suggests that the FRED™ X™ device is safe for brain aneurysm treatment?

Research has shown that the FRED™ X™ device is generally safe for treating brain aneurysms. In a study with 154 patients using the FRED™ X™ device, the treatment was well-tolerated. Another study found that nearly all patients with unruptured aneurysms experienced good neurological outcomes, suggesting the device works effectively without causing many serious side effects.

Additionally, a comparison study found that the FRED™ X™ device not only improved treatment success rates but also maintained a safety profile similar to the original FRED™ device. These findings suggest that the FRED™ X™ device is a promising option with low complication rates, making it a safe choice for those considering joining a clinical trial. ^{1 2 3 4 5}

Why are researchers excited about this trial?

The FRED™ X™ device is unique because it offers a novel approach to treating brain aneurysms by using a specialized flow-diversion mechanism. Unlike traditional options like surgical clipping or endovascular coiling, which directly seal or fill the aneurysm, FRED™ X™ redirects blood flow away from the aneurysm, promoting natural vessel healing. Researchers are excited about this device because it may reduce the risk of rupture with potentially fewer complications and quicker recovery times compared to conventional treatments.

What evidence suggests that the FRED™ X™ device is effective for brain aneurysms?

Research shows that the FRED™ X™ device, studied in this trial, holds promise for treating brain aneurysms. One study found that 64.9% of aneurysms were completely closed at 6 months, improving to 79.5% at 12 months and 85.5% at 24 months. Another study reported better closure rates with the FRED™ X™ device after one year compared to the earlier FRED™ device, while maintaining patient safety. Additionally, all cases of ruptured aneurysms had good outcomes, though complete closure occurred in 59.65% of these cases. These results suggest that the FRED™ X™ device effectively and safely manages brain aneurysms over time. ^{1 3 4 5 6}

Are You a Good Fit for This Trial?

This trial is for adults with a wide-necked brain aneurysm located in the internal carotid artery, who are not pregnant or breastfeeding, can undergo imaging without allergic reactions, and have no major heart issues or bleeding disorders. Participants must be able to attend follow-up visits for up to 5 years and sign consent forms.

Inclusion Criteria

I can commit to returning for follow-up visits up to 5 years.

Female participants must have a negative pregnancy test if they have had their period in the last 18 months.

I can carry out all my usual duties with no more than slight disability.

Exclusion Criteria

You have a known allergy to contrast dye or a condition that prevents getting imaging tests.

Subject is enrolled in another device or drug study in which participation could confound study results.

I have a narrowed artery near my brain aneurysm.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive the FRED™ X™ device and are monitored for initial safety and effectiveness

4 weeks

1 visit (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment, including assessment of aneurysm occlusion and parent artery stenosis

12 months

Multiple visits (in-person)

What Are the Treatments Tested in This Trial?

Interventions

• FRED™ X™

Trial Overview

The FRED™ X™ device is being tested in this study. It's designed to treat brain aneurysms by redirecting blood flow. The performance of FRED™ X™ will be compared with the original FRED™ device based on previously established goals from the pivotal study of the latter.

How Is the Trial Designed?

Group I: Flow Re-Direction Endoluminal Device X Experimental Treatment 1 Intervention

FRED™ X™ device

FRED™ X™ is already approved in United States, European Union for the following indications:

Approved in United States as FRED X for:

• Wide-necked saccular or fusiform intracranial aneurysms arising from a parent vessel with a diameter ≥ 2.0 mm and ≤ 5.0 mm

Approved in European Union as FRED for:

• Intracranial aneurysms

Who Is Running the Clinical Trial?

Microvention-Terumo, Inc.

Lead Sponsor

Trials

32

Recruited

7,000+

Published Research Related to This Trial

The FRED X flow diversion device was successfully used in 44 patients with 45 intracranial aneurysms, demonstrating technical feasibility with 100% successful stent placements and promising early safety outcomes, as only 4 patients experienced symptomatic complications.

At 6 months post-treatment, 89% of the aneurysms showed adequate occlusion, indicating effective treatment, while all patients maintained excellent functional outcomes with a modified Rankin Scale score of 0.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

First United States multicenter experience with the new-generation FRED X surface-modified flow diversion stent: feasibility, safety, and short-term efficacy. Abbas, R., Lan, M., Naamani, KE., et al.[2023]

In a study involving 61 patients treated with the FRED flow diverter for intracranial aneurysms, 74.2% achieved complete occlusion of their aneurysms after a median follow-up of 6.3 months, indicating effective treatment outcomes.

The FRED device demonstrated a low complication rate, with only 2.8% experiencing permanent ischemic complications and no procedural mortality, suggesting it is a safe option for patients with intracranial aneurysms.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

The Pennsylvania Postmarket Multicenter Experience With Flow Redirection Endoluminal Device. Salem, MM., Kvint, S., Hendrix, P., et al.[2023]

The Flow Re-direction Endoluminal Device (FRED) demonstrated high efficacy in treating cerebral aneurysms, with 84.6% achieving complete or near-complete occlusion after treatment, particularly effective in smaller and single aneurysms.

The treatment was generally safe, with only 6.5% experiencing major complications, of which only one was clinically relevant, indicating that FRED meets safety standards for intracranial aneurysm treatment.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Efficacy and safety of the dual-layer flow-diverting stent (FRED) for the treatment of intracranial aneurysms. Guimaraens, L., Vivas, E., Saldaña, J., et al.[2020]

In a study involving 20 patients with 24 cerebral aneurysms treated with the Flow Re-Direction Endoluminal Device (FRED), a high complete occlusion rate of 83% was achieved, indicating its efficacy in treating unruptured cerebral aneurysms.

The treatment was found to be safe, with only 4% experiencing intraprocedural complications and no neurological deficits or serious adverse events like aneurysm rupture or hemorrhage reported during follow-up.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Safety and efficacy of flow re-direction endoluminal device (FRED) in the treatment of cerebral aneurysms: a single center experience. Briganti, F., Leone, G., Ugga, L., et al.[2019]

The Flow-Redirection Endoluminal Device (FRED) was successfully deployed in all 50 patients treated for various types of cerebral aneurysms, with no device-related complications reported, indicating a high safety profile.

At 6 months post-treatment, the FRED demonstrated a high occlusion rate of 87.2%, with complete occlusion in 72.3% of patients at 3 months, suggesting its efficacy in effectively treating cerebral aneurysms.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

FRED Flow Diverter: A Study on Safety and Efficacy in a Consecutive Group of 50 Patients. Luecking, H., Engelhorn, T., Lang, S., et al.[2022]

The Flow Re-direction Endoluminal Device (FRED) was successfully deployed in 92.1% of cases for treating cerebral aneurysms, indicating its efficacy in this application.

However, caution is advised when using the FRED in patients with an S-shaped parent vessel or when the device is oversized by more than 2 mm, as these factors were linked to deployment failures.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Efficacy of the Flow Re-direction Endoluminal Device for cerebral aneurysms and causes of failed deployment. Suyama, K., Nakahara, I., Matsumoto, S., et al.[2022]

The FRED device demonstrated an excellent safety profile in treating intracranial aneurysms, with low 1-year morbidity and mortality rates of 2.9% and 1.9%, respectively, in a study involving 103 patients.

Efficacy results showed that 73.3% of patients achieved complete occlusion of their aneurysms at 1 year, indicating that the FRED device is effective for this type of treatment.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

SAFE study (Safety and efficacy Analysis of FRED Embolic device in aneurysm treatment): 1-year clinical and anatomical results. Pierot, L., Spelle, L., Berge, J., et al.[2020]

In a study involving 145 patients with challenging intracranial aneurysms, the Flow Redirection Endoluminal Device (FRED) demonstrated a safety profile with only 6.2% experiencing major complications, well below the performance goal of 15%.

The FRED device also showed effectiveness, achieving complete occlusion in 57.6% of cases, surpassing the effectiveness benchmark of 46%, indicating it is a viable treatment option for selected patients.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Safety and efficacy results of the Flow Redirection Endoluminal Device (FRED) stent system in the treatment of intracranial aneurysms: US pivotal trial. McDougall, CG., Diaz, O., Boulos, A., et al.[2022]

Citations

1.

pubmed.ncbi.nlm.nih.gov

pubmed.ncbi.nlm.nih.gov/40020234/

Long-term safety and efficacy of the FRED X flow diverter ...

This multicenter study presents the largest series within the United States describing the device's efficacy, safety, and long-term outcomes in ...

2.

nature.com

nature.com/articles/s41598-025-90463-9

The evaluation of the flow re-direction endoluminal device ...

Imaging follow-up at 6 months showed complete occlusion of the aneurysm in 64.9% of cases, increasing to 79.5% at 12 months and 85.5% at 24 ...

3.

dirjournal.org

dirjournal.org/articles/short-to-mid-term-outcomes-of-flow-re-direction-endoluminal-device-x-fredlesssupgreatertmlesssupgreater-x-in-the-management-of-intracranial-aneurysms-a-meta-analysis/dir.2025.253309

Short to mid-term outcomes of flow re-direction ...

In addition, favorable outcomes were seen in 100% of ruptured aneurysm cases; however, complete occlusion was achieved in only 59.65%, and the ...

4.

jnis.bmj.com

jnis.bmj.com/content/17/e1/e159

a comparative study of efficacy and safety between FREDX ...

Conclusions The FREDX device shows improved complete occlusion rates at 1 year compared with the FRED device while maintaining a favourable safety profile, ...

5.

thejns.org

thejns.org/view/journals/j-neurosurg/143/1/article-p232.xml

Long-term safety and efficacy of the FRED X flow diverter for ...

This multicenter study presents the largest series within the United States describing the device's efficacy, safety, and long-term outcomes in ...

6.

pubmed.ncbi.nlm.nih.gov

pubmed.ncbi.nlm.nih.gov/39102710/

Safety and efficacy of flow redirection endoluminal device ...

ConclusionFRED had high safety and efficacy in treating IAs, as evidenced by its high occlusion and low complication rates. Keywords: Flow- ...